
Hannah Kuchler
Global Pharmaceuticals Correspondent at Financial Times
Global pharma editor @FT, leading science and pharma team. Emmy-nominated, Loeb winner. Previously NY, SF, HK.
Articles
-
2 weeks ago |
ft.com | Oliver Barnes |Hannah Kuchler
Activist hedge fund Parvus Asset Management is building a stake in Ozempic-maker Novo Nordisk as the drugmaker hunts for a new chief...
-
2 weeks ago |
ft.com | Harry Dempsey |Hannah Kuchler
The Japanese biotech behind Eli Lilly’s new blockbuster obesity pill believes it could be used with an anti-muscle wasting drug it has...
-
3 weeks ago |
ft.com | Hannah Kuchler
US telemedicine platform Hims & Hers is exploring offering replica obesity medicines in the UK and Europe, hoping to offer patients a...
-
3 weeks ago |
ft.com | Oliver Barnes |Hannah Kuchler
UK medical robotics group CMR Surgical has put itself up for sale, seeking a valuation of as much as $4bn as the company plots its launch...
-
3 weeks ago |
ft.com | Hannah Kuchler
Bristol Myers Squibb has signed a partnership worth up to $11bn to develop a BioNTech cancer drug that has the potential to beat the...
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 19K
- Tweets
- 2K
- DMs Open
- Yes

RT @AnnaSophieGross: NEW: AstraZeneca has ditched plans to build new vaccine manufacturing plant in Merseyside, less than a year after it w…

Scoop: AstraZeneca ditches plans to invest in a vaccine manufacturing plant in Speke. With @AnnaSophieGross https://t.co/kg8kvJlzkV

RT @ClaerB: There are high hopes for #bonusseason in the City this year - but how does yours measure up? Early entries to the FT's Bonus Su…